Clinical Trial Update: A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating Salanersen (BIIB115) for movement effects and safety when given pre-symptomatically to genetically diagnosed infants with sp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• Salanersen (BIIB115)

Snippet

Sponsor: Biogen | Conditions: Muscular Atrophy, Spinal | Phase 3 | Status: RECRUITING